Recurrent Head and Neck Carcinoma
Conditions
Brief summary
This pilot clinical trial studies cesium Cs 131 brachytherapy in treating patients with head and neck cancer that has come back (recurrent) and can be removed by surgery. Brachytherapy, also known as internal radiation therapy, uses radioactive material placed directly into or near a tumor to kill tumor cells. Radioactive drugs, such as cesium Cs 131, may carry radiation directly to tumor cells and not harm normal cells. Permanently implanting cesium Cs 131 into the wound bed after surgery may help treat microscopic cancer cells that may be in the tissue after surgical removal of the tumor.
Detailed description
PRIMARY OBJECTIVES: I. Assess the impact of cesium 131 (cesium Cs 131) on recurrence rate, disease free survival and over all survival. SECONDARY OBJECTIVES: I. Assess complications associated with cesium 131 treatment in subjects with head and neck cancer. OUTLINE: Patients undergo brachytherapy using cesium Cs 131 during surgical resection. After completion of study treatment, patients are followed up at 30 days and then every 3 months for 24 months.
Interventions
RADIATIONBrachytherapy
Undergo brachytherapy with Cesium-131
DRUGCesium-131
Undergo brachytherapy with Cesium-131
PROCEDUREConventional surgery
Undergo surgical resection
Sponsors
Sidney Kimmel Cancer Center at Thomas Jefferson University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
1. Diagnosis: Subjects with a diagnosis of recurrent head and neck cancer 2. Based on clinical and radiographic evidence the tumor needs to be deemed resectable preoperatively 3. Age: Subjects must be ≥ 18 years of age and ≤ 90 years old 4. Informed Consent: All subjects must be able to comprehend and sign a written informed consent document
Exclusion criteria
1. Subjects who are pregnant or may become pregnant 2. Unresectable tumor 3. Other severe acute or chronic medical or psychiatric condition that may increase the risk associated with study participation, and in the judgment of the investigator would make the subject inappropriate for entry into this study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Disease free survival (DFS) | Up to 24 months | Will assess the impact of cesium Cs 131 on DFS by comparing the cohort to a matched historical control cohort. The distribution of DFS will be estimated using the Kaplan-Meier and a stratified log rank test will be used to test for differences between cohorts. Adjustment for other potential confounders will be performed using stratified Cox proportional hazards regression |
| Incidence of toxicity | Up to 90 days | Evaluated using the Radiation Therapy Oncology Group Common Toxicity Criteria Categories of risk include infection, wound breakdown, inability to heal, fistula formation, bleeding and need for further surgery. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Recurrence rate | Up to 24 months | Comparisons of 6-month and one-year recurrence rates will be performed using logistic regression |
| Overall survival | Up to 24 months | The distribution of overall survival will be estimated using the Kaplan-Meier and a stratified log rank test will be used to test for differences between cohorts. Adjustment for other potential confounders will be performed using stratified Cox proportional hazards regression. |
| Complication rate | Up to 24 months | Estimated by cohort along with exact 95% confidence intervals |
| Adverse event rate | Up to 30 days | Evaluated using the National Cancer Institute, Common Terminology Criteria for Adverse Events version 4.0 Estimated by cohort along with exact 95% confidence intervals |
Countries
United States
Outcome results
None listed